Intended for UK healthcare professionals only. Promotional content from Boehringer Ingelheim.
About SPIRIVA® Respimat®
SPIRIVA® Respimat® is the only long-acting muscarinic antagonist (LAMA) approved for use in asthma, and establishes a class of medicine in the treatment of patients aged 6 years and above with severe asthma who have experienced a severe exacerbation in the last year.1SPIRIVA® Respimat®(tiotropium) works by reducing cholinergic bronchoconstriction.1
The Respimat® inhaler generates a unique mist of slow-moving, long-lasting fine droplets that is designed to deliver medication deep into your patients’ lungs.2,3
Find out how SPIRIVA® Respimat® could benefit your patients with uncontrolled severe asthma here.
Children as young as 6 years old could inhale successfully from the Respimat® Soft Mist™ inhaler4
95% of children aged 6–12 years (n=92) could inhale successfully from the Respimat® inhaler, without assistance.4,5
- Demonstrated in a handling study of children who received standard training*4
- A successful inhalation manoeuvre was defined as ≥1 correct inhalation in 3 attempts, which were recorded using a pneumotachograph†4
- These children received no help from parents/carers4
How to use a SPIRIVA® Respimat® inhaler every day
SPIRIVA® Respimat<supt® is the only Respimat® licensed for use in children.
The SPIRIVA® Respimat® inhaler is propellent free and reusable with up to six cartridges.1,6 Find out more about the SPIRIVA® Respimat® inhaler here. Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.
SPIRIVA® Respimat® is indicated as an add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
*Single-centre study in children with asthma or atopic disease (n=84) and their healthy siblings with no inhaler experience (n=15). 92 children were aged 6–12 years. All children received standard training with a Respimat® Soft Mist™ inhaler containing no active medication.
†Attempts with any major faults were excluded, including: no actuation, actuation ≥3 seconds before inhalation, actuation after inhalation, exhalation during the inhalation manoeuvre (including coughing triggered by inhalation), inhalation volume ≤0.5 L. Accessories such as spacers were not permitted.
References: 1. SPIRIVA® Respimat® Summary of Product Characteristics. 2. Dalby et al. Medical Devices: Evidence and Research 2011;4:145–55. 3. Ciciliani AM et al. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–77. 4. Kamin W et al. Pulm Ther 2015;1:53–63. 5. Kamin W et al. Pulm Ther 2015;1:53–63, supplementary appendix. 6. Hansel M et al. Adv Ther 2019;36(9):2487–92.
PC-GB-101478 March 2020